Navigation Links
VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
Date:1/20/2010

BEDFORD, Mass., Jan. 20 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 680 FAST™ imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo.  

Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis.  The new Cat B 680 FAST™ agent is designed to complement VisEn's existing in vivo agent product lines, providing early imaging time points and an additional reporting wavelength for more multiplexing choices in cell-based and in vivo research study designs.

"We continue to be very pleased with the rapidly expanding capability and adoption of our fluorescence agents and FMT imaging systems in measuring key biologic pathways and biomarkers in vivo," said Kirtland Poss, President and CEO of VisEn. "The new Cat B 680 FAST™ imaging agent is another new addition to the strong suite of VisEn agents that are becoming increasingly integrated as a standard in disease research today."

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts in vivo.  VisEn offers over 30 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.  VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense®, MMPSense™, Cat K FAST™,  Annexin-Vivo™, and now OsteoSense® 800, VivoTag® 800 and Cat B 750 and 680 FAST™.  VisEn also offers specialized lines of in vivo agent labeling platforms, including its proprietary VivoTag® fluorescence labeling dyes for custom agent development and its NanoSpark® labeling nanoparticles.  They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in in vivo imaging.  

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.  VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and cellular-based imaging systems.  With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking pre-clinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy in vivo.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease. The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific pre-clinical and clinical research areas.

Additional information can be found at www.visenmedical.com.

SOURCE VisEn Medical Inc.

RELATED LINKS
http://www.visenmedical.com

'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
4. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
5. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
6. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
7. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
8. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
9. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
10. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
11. Premier Micronutrient Launches Supplement for Hearing Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... CITY, Mo. , May 3, 2016 /PRNewswire/ ... Kansas Medical Center,s Institute for Advancing Medical Innovation ... and commercialize new drugs, diagnostics and medical devices. ... provides BioNovus Innovations with rights to license, develop ... "This partnership represents ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 ... and endovascular medical technology, today announced Food and ... a cardiac resynchronization defibrillator that provides heart failure ... (MRI) scans. Iperia devices also have remote monitoring ... (CLS) that adapts the heart rate in response ...
(Date:5/3/2016)... , May 3, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... by Field Strength (High Field, Very High Field, Low ... (Brain, Head and Neck, Spine, Musculoskeletal, Vascular, Breast, Pelvic ... global magnetic resonance imaging (MRI) market was valued at ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Michael Lanteri Agency ... created to assist the people of their local community. The agency pledges to ... community leaders. Their hope is to bring awareness to important local causes with ...
(Date:5/5/2016)... ... May 05, 2016 , ... A recent survey by the Midwest ... getting employees to understand and use the free preventive care benefits available to them ... business groups of large, self-insured public and private employers, MBGH found that only 10% ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... agency’s ongoing community enrichment program serving families of greater Dubuque, IA. The current ... duty, reserve and honorably discharged veterans. Donations to Veteran’s Freedom Center may now ...
(Date:5/5/2016)... ... May 05, 2016 , ... A local study examining ... than 40 percent of participating fifth-grade students already have or are at risk ... Clinical Research in the Division of Pulmonary, Allergy and Critical Care Medicine at ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... TIME for ... safety – today announced a new partnership to reach nearly 1 million children with ... in an instant and is the leading cause of accidental death in children one ...
Breaking Medicine News(10 mins):